These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 17503670

  • 21. Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study.
    Streinu-Cercel A, de Gorgolas M, Müller M, Portilla J, Rugina S, Böcher W, Staszewski S, Pulik P, Rowell L, Salgo M, Stoll M.
    HIV Clin Trials; 2008; 9(6):375-86. PubMed ID: 19203903
    [Abstract] [Full Text] [Related]

  • 22. The influence of charge clustering on the anti-HIV-1 activity and in vivo distribution of negatively charged albumins.
    Beljaars L, Floris R, Berkhout B, Smit C, Meijer DK, Molema G.
    Biochem Pharmacol; 2002 May 01; 63(9):1663-73. PubMed ID: 12007569
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients.
    Wright D, Rodriguez A, Godofsky E, Walmsley S, Labriola-Tompkins E, Donatacci L, Shikhman A, Tucker E, Chiu YY, Chung J, Rowell L, Demasi R, Graham N, Salgo M.
    HIV Clin Trials; 2008 May 01; 9(2):73-82. PubMed ID: 18474492
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
    Dwyer DE, Workman C, Hales G, Amin J, Cooper D, Miller J, Alliance Study Group.
    Antivir Ther; 2006 May 01; 11(4):409-19. PubMed ID: 16856614
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P.
    Antivir Ther; 2005 May 01; 10(8):911-6. PubMed ID: 16430196
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection.
    Dybul M, Nies-Kraske E, Dewar R, Maldarelli F, Hallahan CW, Daucher M, Piscitelli SC, Ehler L, Weigand A, Palmer S, Metcalf JA, Davey RT, Rock Kress DM, Powers A, Beck I, Frenkel L, Baseler M, Coffin J, Fauci AS.
    J Infect Dis; 2004 Jun 01; 189(11):1974-82. PubMed ID: 15143462
    [Abstract] [Full Text] [Related]

  • 30. Increased soluble Fas in HIV-infected hemophilia patients with CD4+ and CD8+ cell count increases and viral load and immune complex decreases.
    Daniel V, Süsal C, Weimer R, Zimmermann R, Huth-Kühne A, Opelz G.
    AIDS Res Hum Retroviruses; 2001 Mar 01; 17(4):329-35. PubMed ID: 11242519
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
    Gallien S, Braun J, Delaugerre C, Charreau I, Reynes J, Jeanblanc F, Verdon R, de Truchis P, May T, Madelaine-Chambrin I, Aboulker JP, Molina JM, EASIER ANRS 138 Study Group.
    J Antimicrob Chemother; 2011 Sep 01; 66(9):2099-106. PubMed ID: 21712241
    [Abstract] [Full Text] [Related]

  • 32. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, Godfrey C, Bastow B, Ray MG, Wang H, Coombs RW, McKinnon J, Mellors JW, AIDS Clinical Trials Group 5201 Study Team.
    JAMA; 2006 Aug 16; 296(7):806-14. PubMed ID: 16905786
    [Abstract] [Full Text] [Related]

  • 33. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.
    AIDS; 2008 Aug 20; 22(13):1583-8. PubMed ID: 18670217
    [Abstract] [Full Text] [Related]

  • 34. Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA.
    Swart PJ, Beljaars E, Smit C, Pasma A, Schuitemaker H, Meijer DK.
    J Drug Target; 1996 Aug 20; 4(2):109-16. PubMed ID: 8894971
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
    Bertz RJ, Persson A, Chung E, Zhu L, Zhang J, McGrath D, Grasela D.
    Pharmacotherapy; 2013 Mar 20; 33(3):284-94. PubMed ID: 23456732
    [Abstract] [Full Text] [Related]

  • 36. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
    Reynes J, Arastéh K, Clotet B, Cohen C, Cooper DA, Delfraissy JF, Eron JJ, Henry K, Katlama C, Kuritzkes DR, Lalezari JP, Lange J, Lazzarin A, Montaner JS, Nelson M, O' Hearn M, Stellbrink HJ, Trottier B, Walmsley SL, Buss NE, Demasi R, Chung J, Donatacci L, Guimaraes D, Rowell L, Valentine A, Wilkinson M, Salgo MP.
    AIDS Patient Care STDS; 2007 Aug 20; 21(8):533-43. PubMed ID: 17711378
    [Abstract] [Full Text] [Related]

  • 37. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.
    Poveda E, Rodés B, Labernardière JL, Benito JM, Toro C, González-Lahoz J, Faudon JL, Clavel F, Schapiro J, Soriano V.
    J Med Virol; 2004 Sep 20; 74(1):21-8. PubMed ID: 15258964
    [Abstract] [Full Text] [Related]

  • 38. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M, Swiss HIV Cohort Study Group.
    Arch Intern Med; 2003 Oct 13; 163(18):2187-95. PubMed ID: 14557216
    [Abstract] [Full Text] [Related]

  • 39. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R, Kaul S, Knupp C, Adler M, Cross AP, Dunkle LM, Kelleher T.
    Clin Ther; 1999 Nov 13; 21(11):1853-63. PubMed ID: 10890257
    [Abstract] [Full Text] [Related]

  • 40. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
    Imaz A, Olmo M, Peñaranda M, Gutiérrez F, Romeu J, Larrousse M, Domingo P, Oteo JA, Curto J, Vilallonga C, Masiá M, López-Aldeguer J, Iribarren JA, Podzamczer D, STOPAR study team.
    Antivir Ther; 2013 Nov 13; 18(1):125-30. PubMed ID: 22805174
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.